Compare AKA & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKA | TTRX |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.4M | 107.2M |
| IPO Year | 2021 | N/A |
| Metric | AKA | TTRX |
|---|---|---|
| Price | $8.73 | $5.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $24.33 | $8.00 |
| AVG Volume (30 Days) | 4.7K | ★ 59.1K |
| Earning Date | 05-12-2026 | 05-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $600,208,000.00 | N/A |
| Revenue This Year | $6.14 | N/A |
| Revenue Next Year | $4.89 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.44 | N/A |
| 52 Week Low | $8.42 | $2.57 |
| 52 Week High | $16.38 | $6.75 |
| Indicator | AKA | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.73 | 51.02 |
| Support Level | N/A | $3.92 |
| Resistance Level | $11.42 | $5.33 |
| Average True Range (ATR) | 0.48 | 0.55 |
| MACD | -0.11 | -0.07 |
| Stochastic Oscillator | 14.90 | 20.44 |
a.k.a. Brands Holding Corp is a portfolio of fashion brands, including Princess Polly, Culture Kings, Petal & Pup, and mnml. Through these brands, the company reaches next-generation consumers who seek fashion inspiration on social media and mainly shop online. The portfolio consists of two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company generates the majority of its revenue from the United States.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.